Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized open-label COPD adherence support study
2017-001593-42Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Co-primary endpoint 1: on-time adherence over 24 weeks. Started Feb 2018; status: terminated.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-001593-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001593-42.